Dartmouth-Hitchcock Health Selects Omnicell's Performance Center to Help Develop Centralized Pharmacy Service Center

MOUNTAIN VIEW, Calif., Jan. 29, 2018 /PRNewswire/ -- Omnicell, Inc. (NASDAQ: OMCL) today announced that Dartmouth-Hitchcock Health, based in Lebanon, NH, has selected the Omnicell^® Performance Center^™ to support development of a centralized pharmacy service center at its main campus, with plans for a move to a centralized warehouse in 2019. The Performance Center helps improve business and patient outcomes by combining a cloud-based predictive intelligence platform with ongoing optimization services.

According to recent reports, inpatient drug spending is increasing 25 percent annually, and more than 90 percent of hospital leaders report that price hikes for inpatient drugs have had an effect on managing overall costs.^1,2 Together these trends are pushing hospital leaders to implement tools to help optimize visibility into medication usage and allocation across their health system.

Dartmouth-Hitchcock, named one of the "100 Great Hospitals in America" by Becker's Hospital Review, plans to use the Performance Center to be more strategic in its medication ordering and distribution decisions, ultimately supporting improved patient outcomes by getting patients the right medications at the right time.³ The Performance Center team of supply chain and pharmacy experts will help Dartmouth-Hitchcock's pharmacy team manage shortage and expiration risk, reduce inventory spend, and leverage medication use analytics for cost-benefit evaluation of different medication regimens, leading to better financial outcomes.

"As with other hospitals across the country, the main goal of our pharmacy is to ensure that medications are available to the patients who need them when they need them most," said Thomas J. Siepka, RPh, MS, FACHE, chief pharmacy officer, Dartmouth-Hitchcock. "The Performance Center helps us achieve this goal by showing us where our medications are being used so we can allocate them best throughout our health system. The expert services also help us navigate shortages and identify strategic buying opportunities, positioning both our patient care and financial performance for success."

"The turbulence of medication availability in 2018 further reinforces the need for hospitals to have complete visibility into their medication inventory to provide the best care to their patients," said J. Christopher Drew, president, North American Automation and Analytics for Omnicell. "We applaud Dartmouth-Hitchcock for taking this commitment to elevate their pharmacy operations, and are pleased to have our team of experts work closely with them as they realize new efficiencies within their medication management processes."

About Dartmouth-Hitchcock

DARTMOUTH-HITCHCOCK (D-H) is a nonprofit academic health system serving communities in northern New England. D-H provides access to more than 1,000 primary care doctors and specialists in almost every area of medicine at Dartmouth-Hitchcock Medical Center; the Norris Cotton Cancer Center, the Children's Hospital at Dartmouth-Hitchcock, four affiliate hospitals, 24 ambulatory clinics and through the Visiting Nurse and Hospice for VT and NH. The D-H system trains nearly 400 residents and fellows annually, and performs world-class research, in partnership with the Audrey and Theodor Geisel School of Medicine at Dartmouth and the White River Junction VA Medical Center.

About Omnicell

Since 1992, Omnicell (NASDAQ: OMCL) has been inspired to create safer and more efficient ways to manage medications and supplies across all care settings. As a leader in medication and supply dispensing automation, central pharmacy automation, IV robotics, analytics software, and medication adherence and packaging systems, Omnicell is focused on improving care across the entire healthcare continuum—from the acute care hospital setting, to post-acute skilled nursing and long-term care facilities, to the patient's home.

Over 4,000 customers worldwide use Omnicell^® automation and analytics solutions to increase operational efficiency, reduce medication errors, deliver actionable intelligence and improve patient safety.

Omnicell's innovative medication adherence solutions, used by over 32,000 institutional and retail pharmacies in North America and the United Kingdom, are designed to improve patient adherence to prescriptions, helping to reduce costly hospital readmissions.

Recent Omnicell acquisitions, including Ateb, add distinct capabilities, particularly in central pharmacy, IV robotics, and pharmacy software, creating the broadest medication management product portfolio in the industry.

For more information about Omnicell, Inc. please visit www.omnicell.com

OMCL-G

Editor's Notes:

1. All Omnicell news releases (financial, acquisitions, products, technology etc.) are issued exclusively by PR Newswire and are immediately thereafter posted on the company's external website, omnicell.com.
2. Omnicell and the Omnicell logo design are registered trademarks of Omnicell, Inc.
3. All other brand or product names may be trademarks or registered trademarks of their respective companies.
   

¹ Advisory Board, "Report: Hospital spending on inpatient drugs up nearly 25% annually over two years." October 13, 2016. Accessed January 2018: https://www.advisory.com/daily-briefing/2016/10/13/inpatient-drug-hospital-spending
² NORC at the University of Chicago, "Trends in Hospital Inpatient Drug Costs: Issues and Challenges." October 11, 2016. Accessed January 2018: http://freepdfhosting.com/14f3eeb95d.pdf
³ Becker's Hospital Review, "100 great hospitals in America, 2016." April 19, 2016. Accessed January 2018: https://www.beckershospitalreview.com/lists/100-great-hospitals-in-america-2016.html

SOURCE Omnicell, Inc.

Related Links

http://www.omnicell.com